Heart failure with reduced ejection fraction (HFrEF): a plain-language guide
Heart failure with reduced ejection fraction, usually shortened to HFrEF, means the main pumping chamber of the heart has become weakened and squeezes out 40% or less of the blood inside it with each beat, which causes breathlessness, tiredness and swelling [1,5].
This page provides general information. It does not replace advice from a doctor or another qualified healthcare professional.
Key facts
- Heart failure does not mean the heart has stopped working or is about to stop working. It means the heart cannot pump blood as well as it should [1,2].
- Ejection fraction is the share of blood pushed out of the heart’s main chamber with each beat. A normal figure is between 55% and 70%. HFrEF means 40% or less [2,8].
- Roughly 1% to 2% of adults have heart failure, rising to more than 10% of people aged 70 and over. About half of people in hospital with heart failure have the reduced form [5].
- Around 6.7 million adults in the United States are living with heart failure, and about 1 in 4 people will develop it at some point in life [12].
- Treatment has changed a great deal. Four kinds of medicine now form the standard of care, and the aim is to get every person onto all four [5,13].
- Sudden weight gain of more than 2 kg over about three days can mean fluid is building up and is worth reporting the same day [5].
On this page
- What is heart failure with reduced ejection fraction?
- How common is it?
- What causes it?
- What are the symptoms?
- How is it diagnosed?
- How is it treated?
- Living with HFrEF
- Thinking about a clinical trial?
- Current research
- Support and further information
- Questions people often ask
- Related trialport information
- Sources
- Review information
What is heart failure with reduced ejection fraction?
The name frightens people, and it should not. Heart failure does not mean the heart has stopped or is about to stop working [1,2]. It means the heart cannot pump blood around the body as well as it should [2]. Many people live with it for years [1].
What ejection fraction measures. The left ventricle is the heart’s main pumping chamber. It never empties completely, so doctors measure the share of blood inside it pushed out with each squeeze. A normal heart pumps out 55% to 70% [8]. Heart failure is sorted into three groups by that number [2,5]:
- reduced (HFrEF): 40% or less
- mildly reduced (HFmrEF): 41% to 49%
- preserved (HFpEF): 50% or more
In HFrEF the muscle squeezes weakly, the older name being systolic heart failure. In the preserved form it squeezes normally but has stiffened and fills poorly [8]. Treatment differs, and that form has its own trialport guide.
How common is it?
Around 1% to 2% of adults have heart failure of all kinds, rising from about 1% of people under 55 to more than 10% of those over 70, with 3 to 5 new cases per 1,000 European adults each year. These count diagnosed people only, so the real number is likely higher. Roughly half of people hospitalized with heart failure have the reduced form [5].
In the United States around 6.7 million adults have heart failure, and about 1 in 4 people will develop it at some point. Rates are higher among Black adults, and death rates are higher in rural areas [12]. Sudden worsening is a leading reason people over 65 go into hospital [5], and heart failure remains a leading cause of illness and death worldwide [7].
What causes it?
HFrEF happens when the heart muscle is damaged or weakened. Finding out the cause is part of care, since it can change the treatment [5]. The common causes [1,2,5]:
- A previous heart attack, where a blocked artery starves part of the muscle and leaves permanent damage. Narrowed heart arteries and earlier heart attacks are the most common causes in wealthier countries [5].
- High blood pressure, which strains and weakens the muscle over years. See our guide to high blood pressure.
- Cardiomyopathy, disease of the muscle itself. Some forms run in families, including BAG3-associated dilated cardiomyopathy. Others follow an infection, pregnancy, cancer treatment or heavy drinking.
- Heart valve disease, where a leaking or narrowed valve makes the heart work harder.
- Heart rhythm problems, where a heart beating too fast or irregularly weakens over time.
Other causes include thyroid problems, low iron, kidney disease and cardiac amyloidosis, covered in our guide to ATTR-CM [1,2]. Risk rises with age, obesity and smoking [1].
What are the symptoms?
The three main symptoms are breathlessness, tiredness and swelling of the ankles [5]. Breathlessness comes on with activity at first, then sometimes when lying flat or at night [1,10]. Swelling starts in the feet and can spread up the legs [2]. Many find the tiredness hardest, since ordinary jobs take much longer to recover from [10].
Symptoms are graded using the New York Heart Association classes, by how much they limit you [9]:
- class I: no limit on ordinary activity
- class II: ordinary activity brings on symptoms
- class III: less than ordinary activity brings on symptoms
- class IV: symptoms at rest, and any activity makes things worse
When to seek urgent help. In the United Kingdom, contact a doctor urgently or call NHS 111 if you become breathless lying down or during everyday activity, cough up frothy pink phlegm, or gain weight suddenly [1]. A sudden weight gain of more than 2 kg over about three days usually means fluid, and heart failure teams often ask people to report it the same day [5]. Call 999 or 911 for severe difficulty breathing, gasping or choking, lips or skin turning pale, blue or grey, or if someone passes out [1].
How is it diagnosed?
A family doctor takes a history, examines you and arranges tests, since symptoms alone are not accurate enough [5].
A blood test comes first. Natriuretic peptides are substances the heart releases when under strain. A result below 125 pg/mL for NT-proBNP, or below 35 pg/mL for BNP, makes heart failure unlikely [5]. In England a result above 2,000 ng/L means specialist review and a heart scan within two weeks [4].
A heart scan confirms it. An echocardiogram is an ultrasound of the heart and is the key test: it measures the ejection fraction and checks the valves [4,5,8]. An electrical tracing and a chest X-ray are usually done too, partly to look for other explanations for breathlessness [1,4]. A specialist heart failure team makes the diagnosis [4].
How is it treated?
There is no cure, and treatment does a great deal [1,2]. The outlook has improved considerably since the first treatment trials, and that improvement has been in the reduced form [5].
Four kinds of medicine, described by what they do. These are the four pillars, and each was separately shown to help people live longer or stay out of hospital [5,13]:
- An ACE inhibitor, an ARB or an ARNI, such as ramipril, candesartan or sacubitril valsartan, which block a hormone system that tightens blood vessels and makes the heart work harder. An ARNI also boosts substances that help the body shed salt and water [5,11].
- A beta blocker, such as bisoprolol or carvedilol, which quiets the stress-hormone signal driving a struggling heart, so it beats more slowly and with less force [5,11].
- A mineralocorticoid receptor antagonist, such as spironolactone, which blocks aldosterone, a hormone that makes the body hold on to salt and water [5,11].
- An SGLT2 inhibitor, dapagliflozin or empagliflozin, first developed for diabetes, which make the kidneys pass out more sugar and salt and help whether or not someone has diabetes [5].
Getting onto all four is the goal, and the order matters less than it used to. Rather than one fixed sequence, guidelines aim to have every person on all four, then work the doses up, and they stress getting there quickly [13]. Several ways of doing that have been suggested, including starting all four at once at low doses, though none has been tested in a trial [13]. After a hospital stay, European guidance recommends building doses up quickly before discharge and over the next six weeks [6].
Water tablets ease symptoms. Diuretics such as furosemide clear fluid and ease breathlessness and swelling, though their effect on survival has not been tested as the four pillars have [5].
Devices, surgery and advanced options. An implantable cardioverter defibrillator sits under the skin and can stop a dangerous rhythm. It is recommended where the ejection fraction is 35% or less and symptoms persist after three months of treatment [5]. Cardiac resynchronization therapy is a pacemaker that makes both sides of the heart squeeze in time, for people at the same threshold whose heart tracing shows a delay [5]. Surgery may improve blood flow or repair a valve, and where medicines and devices are not enough a heart transplant is considered, with around 90% of recipients alive at one year [1,5]. A left ventricular assist device is a pump that helps the heart while someone waits for a transplant, or where one is not possible [1,5].
Living with HFrEF
Care is shared between a specialist heart failure team and the family doctor, with a review at least every six months [4]. Being in a heart failure program lowers the risk of going into hospital [5].
Weigh yourself regularly. Fluid shows on the scales before it shows anywhere else [1,2]. Many people are taught to adjust their water tablet or call the team when weight climbs by more than 2 kg in about three days [5].
Salt and fluid are individual, not a blanket rule. Guidance in England says clinicians should not routinely tell people with heart failure to restrict salt or fluid, and should advise only where intake is high or blood sodium is low [4,5].
Cardiac rehabilitation is worth asking about. Everyone diagnosed should be offered a personalized, exercise-based program [1,4]. Pooling 60 trials with 8,728 people, it cut hospital admissions by roughly a third and improved quality of life, whether run at a center, at home or online [14]. Take-up is low, so ask whether you have been referred [14].
Have the flu and pneumococcal vaccinations you are offered, and ask about iron levels and about pregnancy if relevant [1,4,5,6]. If symptoms keep worsening, ask about palliative care, which is about controlling symptoms and living better [1,4]. Predicting the course for one person is uncertain, and guidance asks clinicians to be open about that [4]. Support exists for the anxiety this brings [2].
Thinking about a clinical trial?
Clinical trials test whether a treatment works and is safe. Heart failure research is busy, partly because so much has changed in the last decade. Deciding whether to look into a study is personal, and it helps to take it in steps.
1. Understand what the study is asking
Worth being clear on what a study involves:
- what the researchers want to learn, such as whether a treatment keeps people out of hospital
- what is being studied, and what it is compared with, which may be an existing medicine, a device or a placebo
- how long it lasts, often a year or more for studies counting hospital stays and deaths
- what visits and tests are involved, usually blood tests, heart scans and walking tests, and how much travel each visit means
- the possible benefits and the known and unknown risks, including low blood pressure, dizziness and changes in kidney function or potassium
- what happens at the end, including whether your usual medicines carry on unchanged
2. Consider possible medical suitability
Every trial has rules about who can take part, called eligibility criteria. For an HFrEF study they might include an ejection fraction at or below a set figure such as 40% or 35%, symptoms in a particular New York Heart Association class, a natriuretic peptide level in a set range, already taking the standard medicines at steady doses, kidney function and potassium within limits, no recent hospital stay, and not being pregnant.
trialport’s medifit helps people consider information related to possible medical suitability. It does not diagnose a condition, confirm eligibility or replace formal screening by the study team.
Explore heart failure with reduced ejection fraction clinical trials through trialport
3. Consider whether participation fits your life
A study can look right on paper and still be hard in practice:
- the time each visit takes, and how many visits across the whole study
- travel to the site, and whether that is realistic on worse days
- how it fits around work or caring for someone else
- support from family and friends, and whether someone can come with you
- daily tasks the study may ask for, such as weighing yourself or keeping a symptom diary
- whether you understand the study well enough to decide, and whether it feels right
trialport’s readifit helps people reflect on their understanding, motivation, time, routines, support, emotions and practical arrangements.
4. Ask questions before deciding
Useful questions to put to a research team:
- Why is this study being carried out, and what is already known?
- Would I keep taking my usual heart failure medicines?
- What would I need to do, and for how long?
- What are the known risks, and what is still unknown?
- Could I receive a placebo? A placebo is a dummy treatment with no active medicine, used so researchers can compare results fairly.
- How would my heart be monitored, and who do I contact if I get more breathless?
- What happens if I need to go into hospital during the study?
- Can I leave after joining, and are travel costs covered?
Taking part is voluntary. A person can ask questions, speak with people they trust and choose not to participate.
Search for clinical trials at app.trialport.com.
Current research
- Testing an existing medicine in a wider group. Vericiguat is already approved for heart failure that has recently worsened. The VICTOR trial in 6,105 people with an ejection fraction of 40% or less and no recent worsening did not reduce its main measure, a combination of death from heart causes and hospital stays. Fewer people taking it died, and the lack of effect on hospital stays may reflect how well treated this group already was [15].
- Iron given through a drip. European guidance was updated in 2023 to recommend it where iron is low, to ease symptoms and quality of life. The effect on hospital stays is less certain, and no survival benefit is established [6].
- How to start the four medicines. Several orders and speeds have been proposed, and none has been compared in a trial [13].
Study status checked: 3 August 2026. Research moves quickly, so this list will date. For current information, search at app.trialport.com.
Support and further information
- United Kingdom: the NHS explains the condition and when to get urgent help [1]. The British Heart Foundation has a cardiac nurse helpline, a free booklet and an online community, with pages available aloud and in several languages [2]. Pumping Marvellous is a patient-led heart failure charity [1,2].
- United States: the American Heart Association has plain-language pages on ejection fraction, symptoms, medicines and devices, plus printable trackers [8,10,11]. The Heart Failure Society of America has a section for families [12].
- Worldwide: the European Society of Cardiology publishes patient versions of its guidelines [5].
Coverage varies. Many countries have a general heart charity rather than a heart failure organization, and the clinic is then the best route.
Questions people often ask
Does heart failure mean my heart is about to stop?
No. It means the heart cannot pump as well as it should [1,2].
What does my ejection fraction number mean?
It is the share of blood pushed out of the main pumping chamber with each beat. 55% to 70% is normal, 41% to 49% is mildly reduced, and 40% or less is the reduced form [2,8].
Is HFrEF the same as HFpEF?
No. In HFrEF the muscle squeezes weakly. In the preserved form it squeezes normally but has stiffened and fills poorly. Treatment differs, and it has its own trialport guide [8].
Can it be cured, and can my ejection fraction go up?
There is no cure [1,2]. The number can improve with treatment, and improvement is linked to better outcomes, so ask when yours will next be measured [13].
Why four medicines when I already feel better?
Each was separately shown to help people live longer or stay out of hospital, and the benefits add up. They work on the weakness itself rather than on how you feel today, so they continue when symptoms settle [5,13].
Should I really weigh myself every day?
This is among the most useful things you can do. A gain of more than 2 kg in about three days usually means fluid rather than fat, and can be dealt with early [1,5].
Related trialport information
- Search for heart failure clinical trials
- How trialport works
- medifit and readifit explained
- Questions people ask about clinical trials
- More guides to medical conditions
- Related guide: heart failure with preserved ejection fraction, where the heart squeezes normally but has become stiff
- Related guide: high blood pressure, one of the leading causes of heart failure
- Related guide: ATTR-CM, a build-up of abnormal protein in the heart muscle
- Related guide: BAG3-associated dilated cardiomyopathy, an inherited cause of a weakened heart muscle
Sources
- NHS. Heart failure. Page last reviewed 26 June 2026, next review due 26 June 2029. https://www.nhs.uk/conditions/heart-failure/ Accessed 3 August 2026.
- British Heart Foundation. Heart failure: causes, symptoms and treatment. Page updated 18 July 2025, next review 15 July 2028. https://www.bhf.org.uk/informationsupport/conditions/heart-failure Accessed 3 August 2026.
- National Institute for Health and Care Excellence. Chronic heart failure in adults: diagnosis and management. NICE guideline NG106, published 12 September 2018, last reviewed 3 September 2025. https://www.nice.org.uk/guidance/ng106 Accessed 3 August 2026.
- National Institute for Health and Care Excellence. Chronic heart failure in adults: diagnosis and management. NICE guideline NG106, Recommendations. https://www.nice.org.uk/guidance/ng106/chapter/Recommendations Accessed 3 August 2026.
- McDonagh TA, Metra M, Adamo M, Gardner RS, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599–3726. doi:10.1093/eurheartj/ehab368. Full text read at https://www.pascar.org/uploads/files/2021_ESC_Guidelines_for_HF.pdf Accessed 3 August 2026.
- McDonagh TA, Metra M, Adamo M, Gardner RS, et al.; ESC Scientific Document Group. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2023;44(37):3627–3639. doi:10.1093/eurheartj/ehad195. Full text read at https://sochicar.cl/wp-content/uploads/2023/09/ehad195.pdf Accessed 3 August 2026.
- Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895–e1032. doi:10.1161/CIR.0000000000001063. https://pubmed.ncbi.nlm.nih.gov/35363499/ Accessed 3 August 2026.
- American Heart Association. Ejection Fraction Heart Failure Measurement. Last reviewed 30 May 2025. https://www.heart.org/en/health-topics/heart-failure/diagnosing-heart-failure/ejection-fraction-heart-failure-measurement Accessed 3 August 2026.
- American Heart Association. Classes and Stages of Heart Failure. Last reviewed 21 May 2025. https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure Accessed 3 August 2026.
- American Heart Association. Heart Failure Signs and Symptoms. Last reviewed 29 May 2025. https://www.heart.org/en/health-topics/heart-failure/warning-signs-of-heart-failure Accessed 3 August 2026.
- American Heart Association. Medications Used to Treat Heart Failure. Last reviewed 17 June 2025. https://www.heart.org/en/health-topics/heart-failure/treatment-options-for-heart-failure/medications-used-to-treat-heart-failure Accessed 3 August 2026.
- Bozkurt B, Ahmad T, Alexander K, Baker WL, et al. HF Stats 2024: Heart Failure Epidemiology and Outcomes Statistics. Journal of Cardiac Failure. 2024. doi:10.1016/j.cardfail.2024.07.001. Top 10 takeaways read at https://hfsa.org/hf-stats-2024-heart-failure-epidemiology-and-outcomes-statistics Accessed 3 August 2026.
- Docherty KF, Bayes-Genis A, Butler J, Coats AJS, Drazner MH, Joyce E, Lam CSP. The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction? European Heart Journal Supplements. 2022;24(Supplement_L):L10–L19. doi:10.1093/eurheartjsupp/suac113. https://academic.oup.com/eurheartjsupp/article/24/Supplement_L/L10/6933303 Accessed 3 August 2026.
- Molloy CD, Long L, Mordi IR, Bridges C, et al. Exercise-based cardiac rehabilitation for adults with heart failure: 2023 Cochrane systematic review and meta-analysis. European Journal of Heart Failure. 2023;25(12):2263–2273. doi:10.1002/ejhf.3046. Abstract read at https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:37850321&resultType=core&format=json Accessed 3 August 2026.
- European Society of Cardiology. Vericiguat did not meet its primary endpoint but lowered the risk of cardiovascular death in patients with heart failure. Press release, 30 August 2025. https://www.escardio.org/news/press/press-releases/Vericiguat-did-not-meet-its-primary-endpoint-but-lowered-the-risk-of-cardiovascular-death-in-patients-with-heart-failure/ Accessed 3 August 2026.
Review information
Written by: trialport editorial team
Reviewed by: Keith Berelowitz, Founder and CEO, trialport
Reviewed on: 3 August 2026
Next review due: 3 August 2027
References last checked: 3 August 2026